One of biotech's flashiest startups is finally getting some competition from a pioneer in a brand new field
Amir Nashat finally has some competition.
Nearly two years ago, Polaris’ managing partner pulled together $60 million and some high-profile advisors to launch Dewpoint Therapeutics around a new approach to biology, called biomolecular condensates. Operating as the only biotech in the space since, they’ve landed big-money partnerships with Bayer and Merck, more venture cash and a couple more marquee board members.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.